| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $211.1M | +27.1% |
| Cost of Revenue | $64.8M | +14.6% |
| Gross Profit | $146.3M | +33.6% |
| R&D Expense | $20.2M | +2.7% |
| SG&A Expense | $165.1M | +18.1% |
| Operating Income | -$39.0M | +22.0% |
| Pre-tax Income | -$58.0M | +31.4% |
| Income Tax | -$7.0M | — |
| Net Income | -$51.1M |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $75.6M | -16.4% |
| Accounts Receivable | $77.5M | +19.2% |
| Inventory | $85.6M | +8.7% |
| Current Assets | $249.9M | +2.8% |
| Total Assets | $357.2M | +3.0% |
| Current Liabilities | $82.1M | +20.3% |
| Long-term Debt | $247.5M | — |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$50.9M | +13.0% |
| Capital Expenditures | $6.0M | -1.1% |
| Investing Cash Flow | -$7.0M | +55.0% |
| Financing Cash Flow | $40.4M | -67.9% |
| Free Cash Flow | -$56.9M | +11.9% |
| +39.6% |
| EPS (Basic) | -$1.72 | +42.7% |
| EPS (Diluted) | -$1.72 | +42.7% |
| Total Liabilities |
| $333.6M |
| +13.6% |
| Stockholders' Equity | $23.5M | -55.7% |